Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia

Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease with a high relapse rate. Cytokine receptor targeted therapies are therapeutically attractive but are subject to resistance-conferring mutations. Likewise, targeting downstream signaling pathways has been difficult. Recent success in the develo...

Full description

Bibliographic Details
Main Authors: Zhengqi Wang, Tian Mi, Heath L. Bradley, Jonathan Metts, Himalee Sabnis, Wandi Zhu, Jack Arbiser, Kevin D. Bunting
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Antioxidants
Subjects:
acute myeloid leukemia
Flt3-internal tandem duplication
reactive oxygen species
mitoSox
BH3 mimetic
mTOR inhibitor
Online Access:https://www.mdpi.com/2076-3921/10/6/956

Similar Items

Similar Items